We are advancing a proprietary portfolio of TCR-T product candidates, for which we retain worldwide commercial rights.
TK-8001 is a CD8 TCR-T specific for the Melanoma-associated Antigen Gene-A1, or MAGE-A1. MAGE-A1 is associated with hallmarks of aggressive cancers and poor clinical prognosis, and there is an emerging body of evidence indicating its involvement as a potential driver of tumorigenesis. MAGE-A1 represents an attractive therapeutic target given the high unmet need in MAGE-A1 expressing cancers, no reported protein expression in healthy tissues other than testis and significant consistency of expression between the primary tumor and metastases. As high affinity TCRs specific for MAGE-A1 peptides in humans are eliminated through central tolerance, we believe our HuTCR platform is a differentiated means to discover and select MAGE-A1 specific TCRs with an optimal affinity and high specificity profile.
TK-2504 is an HLA-A*11:01-restricted CD8 TCR-T specific for KRASG12V. KRAS is one of the most frequently mutated oncogenes, expressed in over 25% of all cancers, and acts as a molecular switch leading to activation of many intracellular signaling pathways involved in the regulation of cell growth, cell differentiation and cell death. KRAS mutations are defined as driver mutations, meaning they are responsible for both the initiation and maintenance of cancer. Targeting driver mutations reduces the potential for the tumor to employ immune escape mechanisms, making the KRAS family an ideal target for TCR-T therapy. TK-2504 is currently in preclinical development.
Phase 1/2 Study
|To be Initiated||The IMAG1NE Phase 1/2 trial is an open-label, multi-center Phase 1/2 trial designed to evaluate the safety and efficacy of TK-8001 in patients with MAGE-A1 positive solid tumors.|